You are here
Cancer Research UK has an unusually broad portfolio of cancer-focused projects, a pipeline that rivals most pharmas', and we're ranked second for the number of oncology licenses completed.
Cancer Research UK currently has more than 30 partnered agents in pre-clinical and clinical development, two drugs in phase III trials and five drugs already on the market and benefiting patients.
Cancer Research UK has more than 200 oncology-focused projects under development and potentially available for licensing or collaboration. The projects range from discovery to clinical.
We’ve been involved in the formation of more than 30 spin-outs – some of which have achieved significant exits through acquisition by leading pharmaceutical companies. Read more.